Activity Description
Antibody-drug conjugates (ADCs) are an emerging chemotherapy class with significant ocular side effects. This activity reviews ADC mechanisms, corneal toxicity pathophysiology, and characteristic slit lamp findings, enabling clinicians to identify and manage ADC-associated ocular adverse events including blurred vision, dry eye, and pseudomicrocysts.
The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.
Release Date: 5-29-2026
Expiration Date: 05-28-2027
Target Audience
This accredited educational activity is designed for ophthalmologists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty
